Quest Diagnostics’ (NYSE: DGX) neurology diagnostics division has developed a test to detect amyotrophic lateral sclerosis or Lou Gehrig’s disease. The test is the first of its kind to detect whether the patient has the genetic mutation associated with the disease. The hexanucleotide repeat expansion in the C9orf72 gene is found in up to 39 […]
A molecular blood test that uses biomarkers to detect renal failure following kidney transplants has been launched by Quest Diagnostics (NYSE:DGX). The test could lower healthcare costs tied to kidney transplant failure. It would help physicians detect kidney failure weeks before other tests or clinical symptoms indicate kidney damage. The test, using technology licensed from […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Diagnostic testing company Quest Diagnostics (NYSE:DGX) is looking to grow its healthcare IT business following an increase in fourth-quarter revenue and profits partly from acquisitions made last year. The Madison, New Jersey lab testing giant had sales of $1.86 billion with profits of $189.5 million in the fourth quarter. Last year, Quest Diagnostics made two […]